Sequential therapy with gemcitabine and carboplatin followed by paclitaxel as first line treatment for advanced urothelial cancer

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 362-368

  Kattan, Joseph G ^a   Boutros, Celine Y ^a   Farhat, Fadi S ^a   Chahine, Georges Y ^a   Musallam, Khaled M ^a   Ghosn, Marwan G ^b  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Bladder cancer; Carboplatin; Gemcitabine; Paclitaxel; Sequential therapy

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLADDER CARCINOGENESIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY PELVIS CARCINOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

EID: 84881211094     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4224     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59: 225-49.
2. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 1989;64: 2448-58.
3. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8: 1050-5.
4. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma of the bladder: a cooperative group study. J Clin Oncol 1992;10: 1066-73.
5. Roth B, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12: 2264-70.
6. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docet-axel in patients with advanced or metastatic transitional-cell carci-noma. J Clin Oncol 1997;15: 1853-7.
7. Stadler WM, Kuzer T, Roth B, et al. A phase II trial of single gem-citabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15: 3394-8.
8. Gitliz BJ, Baker C, Chapman Y, et al. A phase II study of gemcita-bine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003;98: 1863-9.
9. Vaughn DJ, Manola J, Dreicer R, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction. A trial of the Eastern Coopera-tive Oncology Group. Cancer 2002;95: 1022-7.
10. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19: 3018-24.
11. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and car-boplatin in advanced transitional cell carcinoma of the urothelial tract. An alternative therapy. Cancer 2003;97: 2180-6.
12. Van Der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cispla-tin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin On-col 2000;18: 3068-77.
13. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transi-tional cell carcinoma of the urothelium: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2005;11: 2298-303.
14. Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicine, plus cisplatin in pa-tients with bladder cancer. J Clin Oncol 2005;23: 4602-8.
15. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cispla-tin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997;80: 1966-72.
16. Hussain M, Vaishampayan V, DU W, et al. Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19: 2527-33.
17. Bellmunt J, Von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol. 2007;25(18S). ASCO Annual Meeting Proceedings Part I.
18. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors pre-dicting outcome of therapy. J Clin Oncol. 1999 Oct;17(10):3173-81.
19. Vandenput I, Vergote I, Neven P, et al. Weekly paclitax-el-carboplatin regimen in patients with primary advanced or re-current endometrial carcinoma. Int J Gynecol Cancer. 2012 May;22(4):617-22.
20. Rozzi A, Nardoni C, Corona M, et al. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study. J Chemother. 2010 Dec;22(6):419-23.